Lexaria Bioscience Corp(LEXX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:10 PM ET (Korea 10/1 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.28 | Insider Own | 2.96% | Shs Outstand | 2.1M | Perf Week | -2.63% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -14.81% | Insider Trans | - | Shs Float | 2.0M | Perf Month | -72.07% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.9 | Inst Own | 5.19% | Short Float | 8.77% | Perf Quarter | -63.29% |
| Income | -0.01B | P/S | 34.91 | EPS this Y | 59.09% | Inst Trans | 0.76% | Short Ratio | 3.12 | Perf Half Y | -73.08% |
| Sales | 0.00B | P/B | 1.1 | EPS next 5Y | 24.86% | ROA | -134.21% | Short Interest | 0.18M | Perf YTD | -65.96% |
| Book/sh | 2.87 | P/C | 1.83 | EPS past 3/5Y | 18.8% 14.16% | ROE | -150.28% | 52W High | -85.42% ($21.60) | Perf Year | -77.96% |
| Cash/sh | 1.72 | P/FCF | - | Sales past 3/5Y | 40.34% 17.53% | ROIC | -161.36% | 52W Low | 12.5% ($2.80) | Perf 3Y | -79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 46.85% | Gross Margin | 48.98% | Volatility(W/M) | 10.75% 23.37% | Perf 5Y | -96.65% |
| Dividend TTM | - | EV/Sales | 14.27 | Sales Y/Y TTM | -68.5% | Oper. Margin | -3862.94% | ATR (14) | 0.98 | Perf 10Y | -94.33% |
| Dividend Ex-Date | - | Quick Ratio | 10.6 | EPS Q/Q | 61.24% | Profit Margin | -3985.58% | RSI (14) | 33.14 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.6 | Sales Q/Q | -100% | SMA20 | -40.61% ($5.3) | Beta | 0.59 | Target Price | $82.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/07/17 | SMA50 | -56.59% ($7.26) | Rel Volume | 0.4 | Prev Close | $3.13 |
| Employees | 7 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -33.33% - | SMA200 | -67.84% ($9.79) | Avg Volume(3M) | 0.06M | Price | $3.15 |
| IPO | 2006/10/10 | Option/Short | No/Yes | Trades | 288 | Volume | 23,134 | Change | 0.64% |
💊 Lexaria Bioscience is a Canadian biotech company developing its proprietary <strong>DehydraTECH™</strong> oral drug delivery technology. Using a fatty acid-based pre-treatment process, it aims to improve the absorption rate and reduce side effects of existing injectables and oral formulations, and is expanding its applications especially into <strong>oral GLP-1 (semaglutide, liraglutide, tirzepatide)</strong> as well as hypertension and CBD. Listed on NASDAQ, it is a nano-cap stock where licensing and partnership agreements serve as the key growth driver.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded less than usual That is 40% of its average volume.
LEXX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,491. Peers typically go for $1,243.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.7%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
BTR Beacon Tactical Risk ETF <0.01% 
FFLS The Future Fund Long/Short ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #540 of 592 in the industry
Based on market cap of $7M.
AIM#536 AIM ImmunoTech Inc $7M PER - 
ENVB#537 Enveric Biosciences Inc $7M PER - 
CANF#537 Can-Fite Biopharma Ltd ADR $7M PER - 
LNAI#539 Lunai Bioworks Inc $7M PER - LEXX#540 Lexaria Bioscience Corp $7M PER - 
FAQ
What kind of company is LEXX?
LEXX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LEXX?
The market cap of LEXX is approximately $7M, ranking 5,618 within its sector.
What is the 52-week high and low for LEXX?
LEXX has recorded a 52-week high of $21.60 and a low of $2.80.
